 |
|
|
 |
Estimating the Burden of Scleroderma Disease in Spain
ANA VILLAVERDE-HUESO, ELENA SÁNCHEZ-VALLE, ELENA ÁLVAREZ, CONSUELO MORANT, PATRICIA E. CARREIRA, MARÍA CONCEPCIÓN MARTÍN-ARRIBAS, RICARD GÈNOVA, ALEJANDRO RAMÍREZ-GONZÁLEZ, and MANUEL POSADA de la PAZ
ABSTRACT. Methods. We estimated scleroderma-based burden of disease following procedures developed for the Global Burden of Disease study to ensure comparability. Results. Despite its low prevalence, scleroderma generated 1732 disability-adjusted life-years (DALY) in Spain in 2001, comprising 562 (32%) years of life lost and 1170 (68%) years lived with disability. Most scleroderma-related DALY (73%) occurred in the population aged 15–54 years. Estimated DALY accounted for 0.59% of other musculoskeletal disorder-related DALY in the European A subregion (countries with low mortality rate in both adults and children in the World Health Organization classification), a significant value in the overall burden of disease. Conclusion. The burden of scleroderma in Spain was high, with disability being the major contributing factor. Burden of disease is an important measure in rare diseases, and may be an important indicator to be considered as a health unit in developed countries. (First Release Oct 1 2007; J Rheumatol 2007;34:2236-42) Key Indexing Terms:
SCLERODERMA From the Instituto de Investigación de Enfermedades Raras, Instituto de Salud Carlos III; Universidad Rey Juan Carlos I; Servicio de Reumatología, Hospital Universitario 12 de Octubre; and Oficina Regional de Coordinación de Salud Mental and Instituto de Salud Pública, Comunidad de Madrid, Madrid, Spain. Supported by Funds for Health Research (Fondo de Investigación Sanitaria), Cooperative Thematic Research Networks (RETICS program), and Epidemiological Research Network for Rare Diseases (REpIER), Grant G03/123 and Grant INERGEN C03/05. A. Villaverde-Hueso, PharmD, Pharmacist; E. Sánchez-Valle, MD, PhD; M.C. Martín-Arribas, PhD; A. Ramírez-González, MPH; M. Posada de la Paz, MD, PhD, Instituto de Investigación de Enfermedades Raras, Instituto de Salud Carlos III; E. Álvarez, MD, Universidad Rey Juan Carlos I; C. Morant, MD, Oficina Regional de Coordinación de Salud Mental, Comunidad de Madrid; P.E. Carreira, MD, Servicio de Reumatología, Hospital Universitario 12 de Octubre; R. Gènova, PhD, Instituto de Salud Pública, Comunidad de Madrid. Address reprint requests to Dr. M. Posada de la Paz, Instituto de Salud Carlos III (Pabellón 11-IIER), Sinesio Delgado 6-8, Madrid, España. E-mail: mposada@isciii.es Accepted for publication July 25, 2007. |
